These 3 Psychedelic Stocks Activated After Trump’s Executive Order

Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.

04/27/2026, 2:38 PM • Investing

These 3 Psychedelic Stocks Activated After Trump’s Executive Order

Trump's April 2026 executive order supporting psychedelic drugs triggered FDA priority vouchers for select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—saw significant stock surges. While promising, these companies face challenges including mounting losses and high valuations, making them speculative investments.

04/27/2026, 12:22 PM • Investing

Wall Street Is Betting on More Than Marijuana

An executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as stable, cash-generating businesses rather than speculative plays.

04/21/2026, 10:31 AM • Investing

Why Compass Pathways Stock Rocketed 40% Today

Compass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.

04/20/2026, 12:02 PM • The Motley Fool

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.

04/20/2026, 11:07 AM • The Motley Fool

The Psychedelic Revolution in Mental Healthcare

Psychedelic therapy is emerging as a transformative treatment model for mental health conditions, particularly treatment-resistant depression and PTSD. Unlike daily medications, psychedelic therapy is an interventional approach administered 1-6 times with durable long-term benefits. Companies like Compass Pathways are advancing FDA trials, while the real investment opportunity may lie in the $10,000-$20,000 treatment services rather than just the drugs themselves. Big Pharma remains cautiously interested but not yet aggressively pursuing the space.

04/17/2026, 4:19 PM • The Motley Fool

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.

02/26/2026, 12:07 PM • Benzinga

Why Did Compass Pathways Stock Rocket Higher Today?

Compass Pathways stock surged 44% after announcing positive Phase 3 clinical trial results for COMP360, its psilocybin-based treatment for treatment-resistant depression. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2024, with trials involving over 1,000 participants showing statistically significant and clinically meaningful results.

02/17/2026, 11:35 AM • The Motley Fool